Perakizumab, currently Novan, presents a significant step in the management against multiple fibrotic diseases. Distinct from traditional therapies, this antibody carefully targets blocks TGF-beta signaling, a major https://harleyirvw636279.blognody.com/50282079/perakizumab-a-potential-treatment-for-scarring-conditions